🕒 Saturday 25 July 2026 Sat, 25 July 2026

Takeovers, mine studies and record quarterly updates drove the week, with buyers chasing companies that put hard numbers around cash flow, reserves and contract wins. Losses were just as sharp where traders sold into reopenings or questioned whether fresh capital and non-binding deals would turn into profits.

Takeover action and strong funds growth drove the week in finance stocks. Big winners came from deal news and fresh money coming onto platforms, while a few profit stories still saw sellers step in.

Small-cap resources names drove the biggest moves this week, with discovery drilling, project studies and funding deals pushing traders into a handful of stocks. The strongest gains came where companies delivered something concrete: thicker ore, bigger reserves, better cash flow or a clearer route to production.

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.

Nanoveu led the week after live drone trials, while Gratifii slumped on deal changes and X2M dropped after a discounted capital raising. Across the tech board, buyers backed real revenue, cash receipts and contract wins, but punished dilution, legal noise and weak post-gap trading.